Endeavor Biomedicines licenses ULK1/2 inhibitor from Sanford Burnham Prebys and the Salk Institute

The exclusive agreement with Endeavor Biomedicines is for an intellectual property portfolio relating to cancer therapeutics and diagnostics that target ULK1/2, a protein involved in cell recycling.

Researchers identify a novel player in acute myeloid leukemia

RNF5 is required for AML growth. The protein could be inhibited or used as a biomarker to improve patient outcomes.

Sanford Burnham Prebys drug enters Phase 1 study for the treatment of tobacco use disorder

A drug discovered in the lab of Nicholas Cosford, Ph.D., professor and deputy director of the NCI-designated Cancer Center at Sanford Burnham Prebys, has entered a Phase 1 clinical study.